Evidence map›Paper›PMID 24409152›Full record

ArticleFrontiers in physiology2014

CD13 promotes mesenchymal stem cell-mediated regeneration of ischemic muscle.

M Mamunur Rahman, Jaganathan Subramani, Mallika Ghosh, Jiyeon K Denninger, Kotaro Takeda, Guo-Hua Fong, Morgan E Carlson, Linda H Shapiro

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M Mamunur RahmanCenter for Vascular Biology, University of Connecticut Health Center Farmington, CT, USA.
Jaganathan SubramaniCenter for Vascular Biology, University of Connecticut Health Center Farmington, CT, USA ; Department of Anesthesiology, Texas Tech University Health Sciences Center Lubbock, TX, USA.
Mallika GhoshCenter for Vascular Biology, University of Connecticut Health Center Farmington, CT, USA.
Jiyeon K DenningerCenter for Vascular Biology, University of Connecticut Health Center Farmington, CT, USA.
Kotaro TakedaCenter for Vascular Biology, University of Connecticut Health Center Farmington, CT, USA.
Guo-Hua FongCenter for Vascular Biology, University of Connecticut Health Center Farmington, CT, USA.
Morgan E CarlsonCenter on Aging, University of Connecticut Health Center Farmington, CT, USA ; Drug Discovery, Genomics Institute of the Novartis Research Foundation San Diego, CA, USA.
Linda H ShapiroCenter for Vascular Biology, University of Connecticut Health Center Farmington, CT, USA.
UConn Health · USTexas Tech University Health Sciences Center · US

Funding

Vascular Pathophysiology and History Core (VPHC)P01HL070694 · NHLBI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI HLA, TIMOTHY TUN · 2002 to 2013
$17.5M
NHLBI NIH HHS P01 HL070694
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are multipotent, tissue-resident cells that can facilitate tissue regeneration and thus, show great promise as potential therapeutic agents. Functional MSCs have been isolated and characterized from a wide array of adult tissues and are universally identified by the shared expression of a core panel of MSCs markers. One of these markers is the multifunctional cell surface peptidase CD13 that has been shown to be expressed on human and murine MSCs from many tissues. To investigate whether this universal expression indicates a functional role for CD13 in MSC biology we isolated, expanded and characterized MSCs from bone marrow of wild type (WT) and CD13(KO) mice. Characterization of these cells demonstrated that both WT and CD13(KO) MSCs expressed the full complement of MSC markers (CD29, CD44, CD49e, CD105, Sca1), showed comparable proliferation rates and were capable of differentiating toward the adipogenic and osteogenic lineages. However, MSCs lacking CD13 were unable to differentiate into vascular cells, consistent with our previous characterization of CD13 as an angiogenic regulator. Compared to WT MSCs, adhesion and migration on various extracellular matrices of CD13(KO) MSCs were significantly impaired, which correlated with decreased phospho-FAK levels and cytoskeletal alterations. Crosslinking human MSCs with activating CD13 antibodies increased cell adhesion to endothelial monolayers and induced FAK activation in a time dependent manner. In agreement with these in vitro data, intramuscular injection of CD13(KO) MSCs in a model of severe ischemic limb injury resulted in significantly poorer perfusion, decreased ambulation, increased necrosis and impaired vascularization compared to those receiving WT MSCs. This study suggests that CD13 regulates FAK activation to promote MSC adhesion and migration, thus, contributing to MSC-mediated tissue repair. CD13 may present a viable target to enhance the efficacy of mesenchymal stem cell therapies.

Indexed as

adhesionCD13cell transplantationhindlimb ischemiamesenchymal stem cells

Identifiers

PMID24409152
PMCPMC3885827
OpenAlexW1986035655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.